BMS sues over generic of blockbuster leukaemia treatment

Bristol-Myers Squibb (BMS) has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel (dasatinib), infringes a pair of patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

BMS says Hengrui’s Abraxane infringes

13 May 2022 A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.

Generics

BMS sues MSN over Pomalyst generic

7 April 2022 Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

18 January 2022 The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.

More features

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

Why AI is changing the patent rules faster than anyone can keep up

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

BMS sues over generic of blockbuster leukaemia treatment

More on this story

Editor's picks

Editor's picks

More features